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Effect of Long-Acting Testosterone Treatment on
Functional Exercise Capacity, Skeletal Muscle
Performance, Insulin Resistance, and
Baroreflex Sensitivity in Elderly Patients
With Chronic Heart Failure
A Double-Blind, Placebo-Controlled, Randomized Study
Giuseppe Caminiti, MD,* Maurizio Volterrani, MD,* Ferdinando Iellamo, MD,*†
Giuseppe Marazzi, MD,* Rosalba Massaro, MD,* Marco Miceli, MD,* Caterina Mammi, MD,*
Massimo Piepoli, MD,‡ Massimo Fini, MD,* Giuseppe M. C. Rosano, MD*
Rome and Piacenza, Italy
Objectives This study investigated the effect of a 12-week long-acting testosterone administration on maximal exercise ca-
pacity, ventilatory efficiency, muscle strength, insulin resistance, and baroreflex sensitivity (BRS) in elderly pa-
tients with chronic heart failure (CHF).
Background CHF is characterized by a metabolic shift favoring catabolism and impairment in skeletal muscle bulk and func-
tion that could be involved in the pathophysiology of heart failure.
Methods Seventy elderly patients with stable CHF—median age 70 years, ejection fraction 31.8  7%—were randomly
assigned to receive testosterone (n  35, intramuscular injection every 6 weeks) or placebo (n  35), both on
top of optimal medical therapy. At baseline and at the end of the study, all patients underwent echocardiogram,
cardiopulmonary exercise test, 6-min walk test (6MWT), quadriceps maximal voluntary contraction (MVC), and
isokinetic strength (peak torque) and BRS assessment (sequences technique).
Results Baseline peak oxygen consumption (VO2) and quadriceps isometric strength showed a direct relation with serum
testosterone concentration. Peak VO2 significantly improved in testosterone but was unchanged in placebo. Insu-
lin sensitivity was significantly improved in testosterone. The MVC and peak torque significantly increased in tes-
tosterone but not in placebo. The BRS significantly improved in testosterone but not in placebo. Increase in tes-
tosterone levels was significantly related to improvement in peak VO2 and MVC. There were no significant
changes in left ventricular function either in testosterone or placebo.
Conclusions These results suggest that long-acting testosterone therapy improves exercise capacity, muscle strength, glucose
metabolism, and BRS in men with moderately severe CHF. Testosterone benefits seem to be mediated by meta-
bolic and peripheral effects. (J Am Coll Cardiol 2009;54:919–27) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.078s
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ihronic heart failure (CHF) is a disease increasingly rec-
gnized as a health burden worldwide. An improvement in
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epartment of Medical Sciences, IRCCS San Raffaele Pisana, Rome, Italy; †De-
artment of Internal Medicine, University of Rome Tor Vergata, Rome, Italy; and the
Department of Cardiology, “Guglielmo da Saliceto” Hospital, Piacenza, Italy. This
tudy was supported by the Italian Ministry of Health, as a part of Finalized Research
005 Grant. This study was also supported, in part, by Agenzia Spaziale Italiana,
rant ASI I/006/06/0 to Dr. Iellamo.s
Manuscript received February 10, 2009; revised manuscript received April 8, 2009,
ccepted April 29, 2009.urvival rate has been reported in CHF in the last decade
1), which should be ascribed mainly to therapeutic strate-
ies targeted to the pathophysiological mechanisms sustain-
ng the progression and worsening of the disease, mainly the
See page 928
rolonged neurohumoral activation. CHF is also character-
zed by, in addition to neurohumoral activation, a metabolic
hift favoring catabolism and impairment in skeletal muscle
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Testosterone Supplementation in HF September 1, 2009:919–27bulk and function; the latter is
involved not only in symptoms
development but even in the
pathophysiology of the heart fail-
ure (HF) syndrome (2).
In men, androgens are impor-
tant determinants of anabolic
function and muscle strength.
Low plasma levels of testosterone
have been reported in patients
with CHF (3–5), and it has been
hypothesized that a relative hy-
potestosteronemia could be in-
volved in the impairment of skel-
etal muscle function and exercise
tolerance that occur in the HF
syndrome (6). Indeed, anabolic
hormone depletion has been re-
ported to be relatively common in
CHF and to carry a negative prog-
nosis (7). Hence, improving the
anabolic status of patients with
CHF could represent an addi-
tional therapeutic target acting on
a pathophysiological mechanism
hat sustains the progression of the disease, possibly affecting
urvival (7).
In the last few years, some reports have suggested the
ffectiveness of testosterone supplementation in improving
he hemodynamic status and New York Heart Association
NYHA) functional class of patients with CHF (6,8–10).
hese studies would seem promising as to the benefits of
estosterone supplementation in patients with CHF; how-
ver, they were limited by the indirect assessment of
ndividual functional capacity and by the evaluation of
uscle performance of small muscle masses (e.g., forearm
uscles). Until now, there were no data on the effect of
estosterone replacement on standard measures of functional
apacity in patients with CHF that carry important prog-
ostic implication, such as oxygen consumption (VO2) and
entilatory efficiency (11,12). In addition, the perfor-
ance (e.g., the strength) of larger weight-bearing mus-
le masses might be more relevant to the effort intoler-
nce of CHF syndrome and to the effect of anabolic drug
upplementation.
Accordingly, the aim of this study was to assess the effects
f a long-acting testosterone treatment, given on top of
ptimal medical therapy, on functional capacity and venti-
atory efficiency in elderly male patients with moderate-to-
evere HF. We also addressed the effect of testosterone on
uadriceps muscle performance to test the hypothesis that
estosterone supplementation could improve functional ca-
acity and ventilatory efficiency through an improvement of
uscle performance. Finally, the effect of testosterone
upplementation on vagally mediated arterial baroreceptor
Abbreviations
and Acronyms
6MWT  6-min walk test
BP  blood pressure
BRS  baroreflex
sensitivity
CHF  chronic heart failure
HF  heart failure
HOMA-IR  homeostasis
model assessment
IM  intramuscular
LVEF  left ventricular
ejection fraction
MVC  maximal voluntary
contraction
NYHA  New York Heart
Association
PSA  prostate-specific
antigen
PT  peak torque
VE/VCO2  ventilation/
carbon dioxide output
VO2  oxygen consumptionardiac reflex sensitivity (BRS) was also addressed, because 4nimal studies have consistently shown that testosterone
dministration improves BRS (13–15), a major negative
rognostic indicator in CHF (16).
ethods
atient population and study design. The study popula-
ion included 70 elderly male patients with CHF. Patients
ere screened and randomized between October 2005 and
ovember 2006, and the final patient completed the study
n February 2007. Subject eligibility was determined at the
nitial screening visit. Patients were selected from the
utpatient department of cardiology and were included in
he study if they had left ventricular ejection fraction
LVEF) 40%, symptomatic HF with NYHA functional
lass II or III, and clinical stability without hospital admis-
ion for HF in the previous 3 months.
Patients were excluded if they had unstable angina or
ecent acute myocardial infarction, history of severe liver or
idney diseases, uncontrolled hypertension, significant pul-
onary disease, erythrocytosis (hematocrit 50%), prostate
ancer, prostate-specific antigen (PSA) 3 ng/ml, severe
ower urinary tract symptoms and lower extremities vascular,
r other diseases that could prevent a symptom limited
xercise test. At baseline and at the end of the study, a blood
ample was drawn from an antecubital vein after an over-
ight fast for determination of serum hormones and routine
aboratory analyses. Serum testosterone, free testosterone,
otal and free PSA, alanine aminotransferase, aspartate
minotransferase, glucose, insulin, creatinine, total choles-
erol, high-density lipoprotein cholesterol, and triglycerides
ere measured. At baseline and at the end of the study, each
atient underwent echocardiographic examination, muscle
trength assessment, and cardiopulmonary exercise test. A
-min walk test (6MWT) was also performed. At baseline
nd at the end of the study, patients underwent BRS
ssessment in the supine position. All patients gave written
nformed consent to participate in the study, which was
pproved by the local ethics committee.
Patients were randomly allocated to receive, on top of
ptimal medical therapy, either intramuscular (IM) long-
cting testosterone undecanoate (1,000 mg Nebido, Bayer-
chering, Berlin, Germany) or IM saline injection at base-
ine and at 6 and 12 weeks. Testosterone and placebo were
ispensed by the Pharmachologic Department, which was
lso responsible for the randomization codes. The drug was
dministered by a nurse, and the investigators were kept
linded on patient treatment. Patients were followed clini-
ally every month until the end of the study.
chocardiographic examination. A complete 2-dimen-
ional, M-mode, and Doppler echocardiogram was per-
ormed at baseline and at the end of the study by the same
hysicians unaware of clinical and study data, according to
he recommendations of the American Society of Echocar-
iography (17), with an Acuson Sequoia device and a 2.5- to
.25-MHz wide-angle phased-array transducer. Left ven-
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September 1, 2009:919–27 Testosterone Supplementation in HFricular volumes were measured from the apical 4- and
-chamber views. LVEF was calculated with the Simpson’s
ule algorithm.
uscle performance assessment. Assessment of leg mus-
le strength was performed by a computer-based multifunc-
ional dynamometer system (REV 9000, Technogym,
ambettola, Forlì, Italy) in the seated position (18). Muscle
trength was determined during both isometric and isoki-
etic effort. Isometric strength was defined as the highest
orce developed by the patients in 3 5-s maximal voluntary
ontractions (MVCs) separated by 1 min rest. Isokinetic
trength was assessed by evaluating the highest peak torque
chieved in a 5-maximal repetition test of concentric knee
xtension/flexion performed at 90°/s (18). The range of
otion was 70°. During the exercises, the lever arm of the
ynamometer was placed parallel to the limb, with the axis
f rotation coinciding as close as possible with the axis of
otation of the knee joint (19). The distal end of the lever
rm was attached to the inferior third of the dominant leg,
nd the foot was not in contact with the floor. The
oncontracting leg was maintained flexed at 90° at the knee
nd not in contact with the floor (18). Maximal strength
ests were performed after 5 min of warm-up consisting of
nloaded cycling and leg stretching. Twenty minutes were
llowed between the maximal strength tests. Quadriceps
uscle fatigue was automatically calculated by the dyna-
ometer software program through a fatigue index (work
erformed last repetition/work performed first repetition 
00) along with power output.
ssessment of functional capacity and cardiorespiratory
ndexes. Functional capacity was assessed by the cardiopul-
onary exercise test and 6MWT at baseline and at the end
f the study. Cardiopulmonary exercise test was performed
t the enrollment and at the end of the study with an
lectrically braked bicycle ergometer with monitoring of gas
xchange (Vmax 29 C, SensorMedics, Yorba Linda, Cali-
ornia). Exercise started with 1 min of unloading pedaling
nd increased by 10 W every minute until exhaustion
defined as the inability to keep the pedaling rate steady at
0 rpm). Peak VO2 was defined as the highest VO2
bserved during exercise averaged for a 30-s recording
uring the last minute. Respiratory exchange ratio was
alculated at the same time-point. A value 1.10 was taken
o represent adequate effort. The ventilation/carbon dioxide
utput (VE/VCO2) slope, which relates the rate of increase
n ventilation/unit increase in carbon dioxide, was calculated
or the whole exercise period. A 12-lead electrocardiogram
as recorded continuously, and blood pressure (BP) was
easured every 2 min by a sphygmomanometer. The
MWT was performed according to standardized proce-
ures (20).
nsulin resistance. Glucose and insulin were measured
fter an overnight fasting. The blood samples were collected
n 5-ml tubes, immediately placed on ice, and transferred to
he biochemistry laboratory where samples were processed.
lasma insulin levels were measured by immunoradiometric Tssay with a commercially available kit (DiaSorin, Inc.,
eutlinger, Germany). Insulin resistance was estimated by
he homeostasis model assessment (HOMA-IR) (21).
RS assessment. We also assessed BRS in a subgroup of
atients by the sequences technique (22) by analyzing
imultaneous recordings of noninvasive finger beat-by-beat
P (Finapres, Ohmeda 2350, Englewood, Colorado) and
he electrocardiographic trace from a precordial lead at a
ampling rate of 250 Hz (Biopac system, Goleta, Califor-
ia), as described in detail previously (23,24), during 10 min
f supine rest. The sequences method allows a quantifi-
ation of the BRS at the current prevailing levels of
rterial pressure and R-R interval and reflects vagally
ediated baroreflex responses (22,25,26). Additional ex-
lusion criteria for BRS assessment were atrial fibrillation
nd/or frequent premature supraventricular or ventricular
ctopic beats, which would have prevented reliable BRS
easurements.
tatistical analysis. The sample size for the study was
alculated on the basis of previous studies (9) showing that
-month testosterone treatment led to a 70% increase in
alking distance in CHF subjects versus control subjects.
e estimated an overall need of 70 patients to obtain the
ame effect size with 80% power and 5% significance,
ssuming a dropout rate of 15%.
Differences in baseline characteristics between treatment
nd placebo groups were evaluated by the chi-square and
npaired t test. Within-group changes in the reported
ariables were evaluated by the paired t test or Wilcoxon
igned rank test for non-normally distributed variables.
etween groups comparisons were performed by the un-
aired t test and Mann-Whitney rank sum test. Relations
etween variables were assessed by Pearson product-
oment correlation or Spearman’s rank test for non-normally
istributed data. Results are expressed as mean  SD. A
-tailed p value of 0.05 was considered significant. All
nalyses were performed with a commercially available statis-
ical package (SPSS for Windows version 12.0, Chicago,
llinois).
esults
rom a total of 96 patients screened, 70 met the inclusion
riteria and were included in the study. Fourteen patients were
ot included, because of renal failure in advanced stage (cre-
tinine clearance 30 mg/dl); 9 patients had PSA levels 3
g/ml; 3 patients had hematocrit 50%. Of 70 patients, 64
ompleted the study protocol: 4 patients in the testosterone
roup and 2 in the placebo group discontinued the study.
he reason for discontinuation, in every case, was the
illingness of the patient to escape from the study (e.g.,
ogistic reasons, moving to another region, autonomous
ecision to discontinue the protocol not related to testos-
erone supplementation).
Baseline characteristics of the patients are reported in
able 1. There were no significant differences between the
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Testosterone Supplementation in HF September 1, 2009:919–27reatment and the placebo groups with respect to all
ariables.
Most of the patients were receiving beta-blockers (86%),
ngiotensin-converting enzyme inhibitors or angiotensin
eceptor antagonists (92%), or diuretics (44%); 41% were
aking aldosterone receptor blockers, and 33% were receiv-
ng digitalis. Medications were not altered throughout the
tudy.
The effect of testosterone supplementation on the differ-
nt variables is reported in Tables 2 and 3. Peak VO2 and
eak workload significantly increased, and VE/VCO2 slope
ignificantly decreased in patients receiving testosterone,
aseline Characteristics of Patients in the 2 GroupsTable 1 Baseline Characteristics of Patients in the 2 Groups
Testosterone
(n  35)
Placebo
(n  35)
Age (yrs), median (interquartile range) 71 (67–76) 69 (66–74)
Cause of heart failure, CAD/IDC 26/9 28/7
NYHA functional class, II/III 18/17 20/15
Diabetes 9 11
Dyslipidemia 21 18
Hypertension 11 14
Atrial fibrillation 14 12
Hypogonadism 12 9
Concomitant therapy
Beta blockers 30 31
ACE inhibitors 32 34
Diuretics 16 17
Aldosterone receptor blockers 16 14
Digoxin 7 8
Antiplatelet agents 21 22
Anticoagulants 16 15
Statins 29 26
ypogonadism was defined as total testosterone 3.5 ng/ml and free testosterone 2.5 pg/ml.
o significant differences were found for any of the comparisons shown. Variables are reported as
bsolute numbers.
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; IDC  idiopathic dilated
ardiomyopathy; NYHA  New York Heart Association.
ardiorespiratory and Muscular Results Before and After 3 MonthsTable 2 Cardiorespiratory and Muscular Results Before and Aft
Testosterone Group (n  31)
Before After
BMI, kg/m2 26.4 3.7 28.7 4.3*†
Body weight, kg 63.5 13.7 66.8 11.4*
SBP, mm Hg 125.6 6.2 121.3 42.7
DBP, mm Hg 92 13.0 80 12.0*
Resting HR, beats/min 74.3 7.2 70 11.5
Peak VO2, ml/kg/min 13.4 4.4 16.3 1.7*†
VE/VCO2 slope 33.6 7.0 29.2 5.1*†
Peak workload, W 78.3 16.0 88.2 18.7*†
6MWT, m 386.6 121.0 472.8 138.4*†
MVC, Nm 116.7 26.3 135.6 21.2*†
PTmax, Nm 74.0 17.4 83.4 16.3*†
EF, % 31.5 9.9 32.1 7.2
LVEDD, mm 68 35.7 66.9 23.2
ata are expressed as mean  SD. *Within groups differences; †between groups differences at p
6MWT 6-min walking test; BMI body mass index; DBP diastolic blood pressure; EF ejection fra
ontraction; Nm  Newton meter; PTmax  isokinetic power torque; SBP  systolic blood pressure; VE/hereas no significant changes in these variables were
etected in the placebo group. Distance walked at the
MWT and NYHA functional class (data not shown)
mproved in both groups, but the increase in the 6MWT
as significant only in patients receiving testosterone sup-
lementation (Table 2).
No significant change in LVEF was detected in either
roup. Both groups showed a tendency toward BP decrease,
ith significant results only for diastolic BP in the
estosterone-treated group.
The MVC and PT significantly improved in testosterone-
reated patients but remained unchanged in the placebo group.
imilarly, both the work output (31.3 16.2 J, p 0.01)
nd the fatigue index (42.4  13.0%, p  0.03) improved
n the treatment group, whereas no significant changes were
etected in the control group (data not shown).
At baseline, 21 patients (30%)—12 in the testosterone
roup and 9 in the placebo group—had total and free
estosterone levels below the normal range (total testoster-
ne 3.5 ng/ml, and free testosterone 2.5 pg/ml). Base-
ine total testosterone levels correlated with peak VO2 (r 
.43, p 0.007), distance reached in the 6MWT (r 0.31,
 0.01), and isometric strength (r  0.30, p  0.002).
otal testosterone and free testosterone both increased with
reatment but remained within the normal physiological
ange (1.5 to 5.7 ng/ml), whereas no significant change was
bserved in the placebo group.
Changes in testosterone levels correlated significantly
ith changes in peak VO2 and MVC (Figs. 1 and 2). There
as no significant relation between basal total testosterone
evels and LVEF.
The effects of testosterone supplementation in patients
ith low-normal (e.g., 12 ng/ml) in comparison with
atients with normal testosterone levels are reported in
ables 4 and 5. In patients with low baseline testosterone
evels, there was a greater improvement in peak VO2 and
stosterone Supplementation TherapyMonths of Testosterone Supplementation Therapy
Placebo Group (n  33) Changes ()
efore After Testosterone Placebo
1 4.4 26.6 3.6 2.4 0.2† 0.5 0.06
7 8.3 65 12.9 0.5 0.02 0.3 0.02
2 46.3 125.0 37.9 3.3 1.2 3.2 0.9
9 11.7 83 11.7 12 3.0 6.4 1.7
6 8.2 71.4 8.7 4.3 1.8 3.2 1.2
8 3.2 14.1 3.6 2.9 0.8† 0.3 0.07
1 9.5 32.6 8.8 4.4 1.0† 1.5 0.4
3 14.2 74.3 18.0 9.9 2.4† 2.0 0.7
9 107.4 428.2 112.0 86.2 14.5† 37.3 8.7
7 26.3 119.7 26.3 18.9 3.3† 3.0 1.1
2 14.4 76.3 19.2 9.6 1.2† 2.1 0.5
8 6.5 32.8 10.4 0.6 0.04 1.0 0.03
.327.2 66.8 25.4 1.1 0.03 0.5 0.03
5.of Teer 3
B
26.
64.
128.
8
77.
13.
34.
77.
390.
116.
74.
33.
67
 0.0
ction; HR heart rate; LVEDD left ventricular end-diastolic diameter; MVCmaximal voluntary
VCO2  ventilation/carbon dioxide output; VO2  oxygen consumption.
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September 1, 2009:919–27 Testosterone Supplementation in HFVC with testosterone supplementation, whereas the im-
rovements in the other exercise performance and metabolic
arameters as well as in VE/VCO2 were not significantly
ifferent between patients with low versus normal baseline
estosterone levels.
The testosterone group showed a significant increase in
ematocrit in comparison with the placebo group (2.3 
.8% vs. 0.8  0.2%, respectively, p  0.001).
The HOMA-IR decreased significantly in the testosterone
roup but remained unchanged in the control group. Body
eight and body mass index significantly increased only in the
estosterone group (from 63.5  13.7 kg to 66.8  11.4 kg,
 0.021, and from 26.4  3.7 kg/m2 to 28.7  4.3 kg/m2,
 0.032) but remained unchanged in the placebo group
from 64.7 8.3 kg to 65 12.9 kg, p 0.09 and from 26.1
.4 kg/m2 to 26.6  3.6 kg/m2, p  0.12).
etabolic and Hormonal Results Before and After 3 Months of TesTable 3 Metabolic and Hormonal Results Before and After 3 M
Testosterone Group (n  31)
Before After
Fasting glycemia, mg/dl 114.8 37.1 119.2 33.5
Fasting insulinemia, U/ml 10.4 2.0 7.9 1.4*†
HOMA-IR 2.6 1.4 1.8 0.8*†
Total cholesterol, mg/dl 142.5 43.7 148.5 39.3
HDL cholesterol, mg/dl 36.3 7.1 36.0 5.7
Triglycerides, mg/dl 131.2 39.7 142.5 44.1
Total testosterone, ng/ml 2.3 1.8 5.2 2.2*†
Free testosterone, pg/ml 11.3 5.6 32.0 11.2*†
Total PSA, ng/ml 1.4 1.1 1.5 1.0
Free PSA, ng/ml 0.4 0.2 0.6 0.3
C-reactive protein, mg/dl 0.3 0.2 0.3 0.2
Creatinine, mg/dl 1.4 0.4 1.5 0.3
ata are expressed as mean  SD. *Within groups differences; †between groups differences at p
HDL  high-density lipoprotein; HOMA-IR  homeostasis model assessment (21); PSA  prost
Figure 1
Relation Between Changes ()
in Total Testosterone Levels and in
Peak VO2 in the Testosterone-Treated Group
In heart failure patients treated with testosterone, there was a significant
direct relationship between the increase in plasma levels of testosterone and
the increase in peak oxygen consumption (VO ).2The BRS significantly increased in the testosterone group
n  10) by 3.7  0.9 ms/mm Hg from a baseline value of
.0  1.3 ms/mm Hg, whereas it did not change signifi-
antly in the placebo group (n  12) (0.3  0.8 ms/mm Hg
rom a baseline value of 6.4  0.7 ms/mm Hg, p  0.01).
The PSA levels, liver and renal functions, and hemoglo-
in levels were not significantly affected by treatment with
estosterone. No side effect requiring discontinuation of
estosterone supplementation occurred throughout the
tudy. No patient died during the follow-up period.
Worsening HF occurred in 2 patients receiving testoster-
ne and in 1 patient in the control group and was managed
nly by increasing the dose of furosemide in 2 patients (1 in
he testosterone and 1 in the control group). Only 1 patient
f the treated group required hospital stay.
rone Supplementation Therapyof Testosterone Supplementation Therapy
Placebo Group (n  33) Changes ()
Before After Testosterone Placebo
111 37.3 116 41.3 4.4 1.3 5.2 2.0
11.0 3.1 10.8 2.8 2.5 0.7† 0.2 0.1
2.5 1.1 2.6 1.0 0.8 0.02† 0.1 0.06
47.3 54.2 150.6 67.3 3.0 1.4 3.2 1.3
37.0 6.2 36.6 6.9 0.3 0.05 0.4 0.02
38.6 32.5 135.2 38.1 11.7 4.3 3.2. 1.5
2.1 2.1 2.3 1.7 2.9 0.6† 0.2 0.1
12.1 6.0 12.4 5.7 21.3 6.4† 0.3 0.2
1.3 0.7 1.4 0.5 0.1 0.02 0.1 0.04
0.4 0.1 0.5 0.1 0.2 0.04 0.1 0.03
0.4 0.2 0.3 0.1 0.3 0.02 0.1 0.02
1.4 0.5 1.4 0.3 0.1. 0.03 0.07 0.01
5.
cific antigen.
Figure 2
Relation Between Changes ()
in Total Testosterone Levels and in
MVC in the Testosterone-Treated Group
In heart failure patients treated with testosterone, there was a significant
direct relationship between the increase in plasma levels of testosterone and
the increase in maximal isometric muscle strength (maximal voluntary contrac-
tion [MVC]).tosteonths
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he results of this study indicate that testosterone supplemen-
ation improves VO2, VE/VCO2 slope, large-muscle perfor-
ance, and BRS in patients with CHF. The relevance of these
ndings should be placed in the context of the established
vidence indicating the adverse prognostic role of low func-
ional capacity, ventilatory efficiency and BRS, and the
eripheral muscle deterioration leading to early fatigue and
imited exercise tolerance that characterize patients with
HF.
The present study shows that testosterone supplementa-
ion given on top of optimal medical therapy improves
unctional capacity, large-muscle strength, and glucose me-
abolism in elderly patients with CHF. The increase in
unctional capacity and muscular strength is related to the
ncrease in plasma levels of testosterone and not related to
hanges in left ventricular function.
Until now only few studies have been conducted on the
ffect of testosterone therapy in CHF. In a 12-week pilot
tudy of 20 CHF patients, Pugh et al. (6) showed that
ntramuscular testosterone therapy improved the distance
alked at the shuttle walking test, without effects on
orearm muscle strength. In a larger placebo-controlled trial,
alkin et al. (9) found that a 12-month testosterone
eplacement therapy improved both distance walked at the
huttle walking test and forearm muscle strength in men
Cardiorespiratory, Muscular, and Metabolic Resof Testo te one Supplementation Therapy in Paand Normal Baseline Testoster e L vels
Table 4
C rdior spiratory, Muscul r, a d M
of Testosterone Supplementation T
and Normal Baseline Testosterone
Low Testosterone Group
Before
Peak VO2, ml/kg/min 11.1 2.4* 1
VE/VCO2 slope 34.0 7.2 2
6MWT, m 369.5 98.2 46
MVC, Nm 92.3 18.1* 13
PTmax, Nm 73.8 17.4 8
HOMA-IR 2.4 (1.9–2.8) 1
Data are expressed as mean SD or as median (interquartile range) f
0.05.
VE/VCO2  ventilation/carbon dioxide output; VO2  oxygen consu
hanges () in Cardiorespiratory, Muscular, andetabolic Parameters Afte 3 Months ofestosterone Suppl men ation Therapy in Patientsith L w (i. ., <12 nmol/l) and Normal BaselineLev ls
Table 5
Changes () in Cardiorespiratory, Muscular, and
Metabolic Parameters After 3 Months of
Testosterone Supplementation Therapy in Patients
With Low (i.e., <12 nmol/l) and Normal Baseline
Testosterone Levels
Low Testosterone Normal Testosterone
Peak VO2, ml/kg/min 4.0 1.8* 2.6 1.2
VE/VCO2 slope 4.9 1.6 4.1 1.5
6MWT, m 96.5 33 80.7 28
MVC, Nm 39.1 6.2* 16.0 5.6
PTmax, Nm 10.0 2.1 10.4 2.1
HOMA-IR 0.5 (0.3–0.7) 0.4 (0.2–0.8)m
ata are expressed as mean  SD or as median (interquartile range) for HOMA-IR. *p  0.05.
Abbreviations as in Tables 2 to 4.ith moderately severe CHF. Assessment of exercise capac-
ty by means of effort tolerance tests such as the 6MWT and
ncremental shuttle walk test is easy to perform, correlates
ith peak VO2, and has been shown to be useful in
rognostic stratification (27–30). However, these assess-
ents do not reflect the overall cardiovascular performance
30) and do not provide any information as to the ventila-
ory efficiency and cardiopulmonary matching during exer-
ise, which play a relevant pathophysiological and prognos-
ic role in CHF (11,12,30,31).
We demonstrated a significant improvement of both peak
O2 and ventilatory efficiency in CHF patients under
estosterone supplementation therapy. This is relevant be-
ause VO2 and VE/VCO2 slope reflect different although
elated aspects of the integrated cardiorespiratory responses
o exercise in HF. Although both VO2 and VE/VCO2 slope
iscriminate individuals at high and low risk for cardiac
ortality in CHF, recent studies have indicated that VE/
CO2 slope could be more useful than VO2 in predicting
uture events (32). This has been explained by the inability
f VO2 to provide information on the ventilatory response
o exercise, which is also markedly altered in CHF syn-
rome (33). Thus, the improvement in functional capacity
nd ventilatory efficiency induced by testosterone supple-
entation might positively affect the prognosis in patients
ith moderate HF. The significant correlation between
estosterone level and VO2 would support the hypothesis
hat the improvement in peak VO2 was related to testos-
erone administration. The lack of any change in the
lacebo group is consistent with this assumption.
This study also extends to larger, weight-bearing muscles,
he previous finding of a testosterone-induced increase in
orearm muscle strength, which is more relevant to the effort
ntolerance of the CHF syndrome. This occurred for both
tatic and dynamic muscular performance, this latter being
ever investigated before.
The improvement in VO2 was greater in patients with
ower baseline testosterone levels as it was the increase in
tatic strength (i.e., MVC). However the improvements in
entilatory efficiency, 6MWT, dynamic muscular perfor-
t Baseline and After 3 MonthsWith Low (i.e., <12 nmol/l)lic Results t Bas line and After 3 Months
y in Patients With Low (i.e., <12 nmol/l)
s
12) Normal Testosterone Group (n  19)
r Before After
2.0† 14.3 2.2 16.9 1.7†
6.0† 33.1 6.1 29.0 5.4†
104.7† 397.9 100.4 478.6 93.2†
21.2† 124.66 15.3 140.6 21.2†
12.3† 74.0 17.4 84.4 11.3†
–2.2)† 2.2 (1.8–2.5) 1.8 (1.4–2.3)†
A-IR. *Between groups differences; †within groups differences at p
; other abbreviations as in Tables 2 and 3.ults atientsetabo
herap
Level
(n 
Afte
5.1
9.8
6.0
1.6
3.8
.9 (1.5
or HOMance and insulin sensitivity did not differ significantly
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his would indicate that the benefits of testosterone sup-
lementation are not entirely confined to HF patients with
ow baseline testosterone, although a greater improvement
n some physiological parameters in these patients would be
xpected.
The mechanism(s) through which testosterone affects
ardiorespiratory indexes is still unclear. However, our data
n muscle performance might provide some insights. We
bserved a significant increase in both static and dynamic
eg strength in addition to a reduced fatigue index and
mproved work output in the testosterone-treated group.
hese effects would depend on the action of testosterone at
he muscular level. Objective morphological and functional
bnormalities, relatively independent of reduced blood flow,
re present in the muscle of CHF patients (34). These
aladaptive changes in the muscles, which include fiber
trophy and a prevalence of type II fibers with a predomi-
ance of glycolytic over oxidative metabolism, are involved
ot only in symptoms development but even in the patho-
hysiology and worsening of the HF syndrome, the so-
alled “muscle hypothesis” (2). In short, by this hypothesis,
uscle alterations occurring in CHF would elicit—in
ime—an enhanced muscle metaboreflex (also called ergore-
ex) (35) activation even at moderate levels of exercise that
n turn would be responsible for the prolonged neurohu-
oral activation and abnormal hemodynamic, autonomic,
nd ventilatory responses to exercise that characterize CHF
35–37). In this context, a strong link has been demon-
trated between muscle metaboreflex overactivity and in-
reased VE/VCO2 slope in CHF (38). Interventions spe-
ifically targeted at reversing peripheral muscle alterations
uch as exercise training have been shown to improve
uscle structure and function and reduce muscle metabore-
ex overactivity and ventilatory response to exercise in CHF
n addition to improving VO2 (34,35,39).
The increase in leg muscle strength and work output
bserved in the present investigation after testosterone
upplementation, which reflects an improvement in overall
uscle function, might have acted in the same manner, by
ecreasing the muscle metaboreflex contribution to ventila-
ory response to exercise, thus reducing VE/VCO2 slope
nd improving ventilatory efficiency. Indeed, anabolic ad-
inistration at replacement doses has been shown to accel-
rate fast- to slow-oxidative fiber type conversion (40)—
hich are typically reduced in CHF patients (34)—and
ncrease the number and size of type I slow oxidative fibers
41), which imply an improved oxidative capacity of skeletal
uscles and a higher aerobic potential with a delayed
atigue. In addition, the small but significant increase in
ematocrit observed in the testosterone-treated group (42)
ight have also contributed to reduction of muscle
etaboreflex activation and, in turn, the ventilatory re-
ponse by improving oxygen availability to the exercising
uscles. This would explain the similar improvement in lE/VCO2 slope in patients with low and normal testoster-
ne levels.
As far as the metabolic profile is concerned, we found a
ignificant reduction of insulin resistance in the testosterone-
reated group. In recent years the prevalence of insulin
esistance in CHF and its role on CHF development have
een elucidated (43,44). Effects of testosterone replacement
n insulin resistance have led to divergent findings, with
ither no changes (45) or significant improvements of
OMA-IR (46) being reported. In the only small study
onducted in nondiabetic CHF patients, testosterone im-
roved insulin sensitivity with an increase in total body mass
nd a reduction in fat mass (47), a finding confirmed in the
resent investigation on a larger sample size.
Another novel and potentially relevant finding of the
resent investigation is the significant increase in BRS
etected in the testosterone-treated group. This would add
urther to the benefits of testosterone, because it is well
nown that BRS is depressed in CHF carrying a negative
rognosis (16,48). Hence, any intervention capable of in-
reasing BRS should be regarded as protective in CHF
yndrome. The mechanism(s) through which testosterone
ould enhance BRS cannot be defined by the present
nvestigation. Several animal studies have shown that tes-
osterone facilitates baroreceptor control of heart rate
hrough an enhancement of cardiac efferent vagal activity
13–15). This effect is likely to occur at central nervous
ystem sites, because androgen receptors have been charac-
erized in brainstem nuclei involved in baroreflex cardiac
egulation (49), and a competitive androgen receptors
locking drug that penetrates the blood brain barrier was
apable of attenuating BRS (15). Nevertheless, although
imited by the small sample size, our finding of an increase
n BRS induced by testosterone supplementation is in a
irection that has been associated with a better outcome in
HF.
We did not find, in agreement with previous studies, any
ignificant change in LVEF. The lack of effects of testos-
erone on left ventricular function seems to confirm that
estosterone acts only through peripheral mechanisms.
In our study there was high compliance: overall only 8%
f patients were lost during the follow-up, a much lower
ercentage than in the study of Malkin et al. (9). Possible
xplanations for these differences are the shorter follow-up
eriod and, mainly, the route of administration of testos-
erone. Malkin et al. (9) used a transdermal patch that was
oorly tolerated, with a substantial number of skin reactions
55% of cases). We used a very-long-acting IM testosterone,
ntil now used only in the treatment of hypogonadism (50),
hich required only 3 administrations and as a consequence
as well tolerated by all patients. More data are needed on
ong-term safety of testosterone supplementation in patients
ith CHF before such therapy could be widely employed in
his patient population. However, our data on the safety of
ong-acting IM testosterone seem promising.
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Testosterone Supplementation in HF September 1, 2009:919–27tudy limitations. Although in our study testosterone
upplementation therapy improved both VO2 and VE/
CO2 slope and BRS, 3 strong prognostic indicators in
HF, the follow-up was short, and we cannot comment on
linical outcome. This is the main limitation of the study.
owever, the present study would indicate that testosterone
upplementation therapy improves clinical measures that
arry adverse effects and negative prognosis in CHF. In
ddition, our data on BRS, although consistent, are limited
o a small sample size. Finally, the increase of muscle
trength and performance we observed after testosterone
upplementation therapy was likely related to changes in
keletal muscle ultrastructure and biochemistry, but we have
o direct data about these changes.
onclusions
ong-term testosterone supplementation improves func-
ional capacity and baroreflex control of heart rate, muscle
trength, and glucose metabolism in elderly patients with
HF. Long-acting IM administration of the drug is well
olerated by CHF patients. Testosterone benefits on CHF
eem to be mediated by metabolic and peripheral effects.
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ipartimento di Medicina Interna, IRCCS San Raffaele Pisana,
niversità di Roma “Tor Vergata,” Via O. Raimondo, 8 00173
ome, Italy. E-mail: iellamo@med.uniroma2.it.
EFERENCES
1. Levy D, Kenchaian S, Larson MG, et al. Long-term trend in the
incidence of and survival with heart failure. N Engl J Med 2002;347:
1397–402.
2. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA.
Symptoms and quality of life in heart failure: the muscle hypothesis. Br
Heart J 1994;72:S36–9.
3. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and
catabolic/anabolic imbalance in chronic heart failure and their impor-
tance for cardiac cachexia. Circulation 1997;96:526–34.
4. Moriyama Y, Yasue H, Yoshimura M, et al. The plasma levels of
dehydroepiandrosterone sulfate are decreased in patients with chronic
heart failure in proportion to the severity. J Clin Endocrinol Metab
2000;85:1834–40.
5. Kontoleon PE, Anastasiou-Nana MI, Papapetrou PD, et al. Hor-
monal profile in patients with congestive heart failure. Int J Cardiol
2003;87:179–83.
6. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone
treatment for men with chronic heart failure. Heart 2004;90:446–7.
7. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with
chronic heart failure prevalence and detrimental impact on survival.
Circulation 2006;114:1829–37.
8. Pugh PJ, Jones TH, Channer KS. Acute haemodynamic effects of
testosterone in men with chronic heart failure. Eur Heart J 2003;24:
909–15.
9. Malkin CJ, Pugh PJ, West JN, Van Beek EJR, Jones TH, Channer
KS. Testosterone therapy in men with moderate severity heart failure:
a double-blind randomized placebo controlled trial. Eur Heart J
2006;27:57–64.
0. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on
insulin sensitivity in men with heart failure. Eur J Heart Fail
2007;9:44–50.1. Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure.
A statement from the American Heart Association Committee
3on Exercise, Rehabilitation and Prevention. Circulation 2003;107:
1210 –25.
2. Swedberg K, Cleland J, Dargie H, et al. Guidelines on the diagnosis
and treatment of chronic heart failure: executive summary (update
2005). The task force for the diagnosis and treatment of chronic heart
failure of the European Society of Cardiology. Eur Heart J 2005;26:
1115–40.
3. El-Mas MM, Afify EA, Mohy El-Din MM, Omar AG, Sharabi FM.
Testosterone facilitates the baroreceptor control of reflex bradycardia:
role of cardiac sympathetic and parasympathetic components. J Car-
diovasc Pharmacol 2001;38:754–63.
4. El-Mas MM, Afify EA, Omar AG, Sharabi FM. Cyclosporine
adversely affects baroreflexes via inhibition of testosterone modulation
of cardiac vagal control. J Pharmacol Exp Therap 2002;301:346–54.
5. Ward GR, Abdel-Rahman AA. Orchiectomy or androgen receptor
blockade attenuates baroreflex-mediated bradycardia in conscious rats.
BMC Pharmacol 2006;6:2.
6. Mortara A, La Rovere MT, Pinna GD, et al. Arterial baroreflex
modulation of heart rate in chronic heart failure. Clinical and hemody-
namic correlates and prognostic implications. Circulation 1997;96:
3450–8.
7. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy. American Society Echocardiography Committee on Standards,
Subcommittee on Quantitation of two-dimensional echocardiograms.
Am Soc Echocardiogr 1989;2:358–67.
8. Iellamo F, Legramante JM, Raimondi G, et al. Effects of isokinetic,
isotonic and isometric submaximal exercise on heart rate and blood
pressure. Eur J Appl Physiol 1997;75:89–96.
9. Iellamo F, Massaro M, Raimondi G, Peruzzi P, Legramante JM. Role
of muscular factors in cardiorespiratory responses to static exercise:
contribution of reflex mechanisms. J Appl Physiol 1999;86:174–80.
0. ATS Committee on Proficiency Standards for Clinical Pulmonary
Function Laboratories. ATS statement: guidelines for the six-minute
walk test. Am J Respir Crit Care Med 2002;166:111–7.
1. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF,
Turner RC. Homeostasis model assessment: insulin resistance and
-cell function from fasting plasma glucose and insulin concentrations
in man. Diabetologia 1985;28:412–9.
2. Bertinieri G, Di Rienzo M, Cavallazzi A, Ferrari AV, Pedotti A,
Mancia G. Evaluation of baroreceptor reflex by blood pressure
monitoring in unanesthetized cats. Am J Physiol 1988;254:H377–83.
3. Legramante JM, Massaro M, Raimondi G, Iellamo F. Positive and
negative feedback mechanisms in the neural regulation of the cardio-
vascular function in healthy and spinal cord-injured humans. Circula-
tion 2001;103:1250–5.
4. Iellamo F, Galante A, Legramante JM, et al. Altered autonomic
cardiac regulation in individuals with Down syndrome. Am J Physiol
Heart Circ Physiol 2005;289:H2387–91.
5. Parlow J, Viale JP, Annat A, Hughson R, Quintin L. Spontaneous
cardiac baroreflex in humans: comparison with drug-induced re-
sponses. Hypertension 1995;25:1058–68.
6. Parati G, Di Rienzo M, Mancia G. How to measure baroreflex
sensitivity: from the cardiovascular laboratory to daily life. J Hypertens
2000;18:7–19.
7. Morales FJ, Martinez A, Mendez M, et al. A shuttle walk test for
assessment of functional capacity in chronic heart failure. Am Heart J
1999;138:291–8.
8. Lewis ME, Newall C, Townend JN, Hill SL, Bonser RS. Incremental
shuttle walk test in the assessment of patients for heart transplantation.
Heart 2001;86:183–7.
9. Morales FJ, Montemayor T, Martinez A. Shuttle versus six-minute
walk test in the prediction of outcome in chronic heart failure. Int
J Cardiol 2000;76:101–5.
0. Fleg JL, Pina IL, Balady GJ, et al. Assessment of functional capacity in
clinical and research applications. An advisory from the Committee on
Exercise, Rehabilitation and Prevention, Council on Clinical Cardiology,
American Heart Association. Circulation 2000;102:1591–7.
1. Francis D, Shamin W, Davies LC, et al. Cardiopulmonary exercise
testing for prognosis in chronic heart failure: continuous and indepen-
dent prognostic value from VE/VCO2 slope and peak VO2. Eur
Heart J 2000;21:154–61.2. Arena R, Myers J, Abella J. Development of a ventilatory classification
system in patients with heart failure. Circulation 2007;115:2410–7.
33
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
K
927JACC Vol. 54, No. 10, 2009 Caminiti et al.
September 1, 2009:919–27 Testosterone Supplementation in HF3. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and
prognostic significance of the ventilatory response to exercise in
chronic heart failure. J Am Coll Cardiol 1997;29:1585–90.
4. Hambrecht R, Fiehn E, Yu J, et al. Effects of endurance training on
mitochondrial ultrastructure and fiber type distribution in skeletal
muscle of patients with stable chronic heart failure. J Am Coll Cardiol
1997;29:1067–73.
5. Piepoli M, Clark AL, Volterrani M, Adamopoulos S, Sleight P, Coats
AJS. Contribution of muscle afferents to the hemodynamic, auto-
nomic, and ventilatory responses to exercise in patients with chronic
heart failure. Effects of physical training. Circulation 1996;93:940–9.
6. Piepoli MF, Kaczmarek A, Francis DP, et al. Reduced peripheral
skeletal muscle mass and abnormal reflex physiology in chronic heart
failure. Circulation 2006;114:126–34.
7. Iellamo F, Sala-Mercado JA, Ichinose M, et al. Spontaneous barore-
flex control of heart rate during exercise and muscle metaboreflex
activation in heart failure. Am J Physiol Heart Circ Physiol 2007;293:
H1929–36.
8. Ponikowski PP, Chua TP, Francis DP, Capucci A, Coats AJS, Piepoli
MF. Muscle ergoreceptor overactivity reflects deterioration in clinical
status and cardiorespiratory reflex control in chronic heart failure.
Circulation 2001;104:2324–30.
9. Piepoli MF, Scott AC, Capucci A, Coats AJ. Skeletal muscle training
in chronic heart failure. Acta Physiol Scand 2001;171:295–303.
0. Czesla M, Mehlhorn G, Fritzsche D, Asmussen G. Cardiomyoplasty-
improvement of muscle fibre type transformation by anabolic steroid.
J Mol Cell Cardiol 1997;29:2989–96.
1. Ustünel I, Akkoyunlu G, Demir R. The effect of testosterone on
gastrocnemius muscle fibres in growing and adult male and female rats:
a histochemical, morphometric and ultrastructural study. Anat Histol
Embryol 2003;32:70–9. c2. Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin
S. Effects of graded doses of testosterone on erythropoiesis in healthy
young and older men. J Clin Endocrinol Metab 2008;93:914–9.
3. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic
heart failure: relation to severity and etiology of heart failure. J Am
Coll Cardiol 1997;30:527–32.
4. Ingelsson E, Sundstrom J, Amlov J, Zethelius B, Lind L. Insulin
resistance and risk of congestive heart failure. JAMA 2005;294:
334 – 41.
5. Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone
supplement on insulin sensitivity, glucose effectiveness, and acute
insulin response after glucose load in male type 2 diabetics. Endocr Res
2005;31:139–48.
6. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone
replacement therapy improves insulin resistance, glycaemic control,
visceral adiposity and hypercholesterolaemia in hypogonadal men with
type 2 diabetes. Eur J Endocrinol 2006;154:899–906.
7. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on
insulin sensitivity in men with heart failure. Eur J Heart Fail
2007;9:44–50.
8. Eckberg DL, Sleight P. Congestive heart failure. In: Eckberg DL,
Sleight P, editors. Human Baroreflexes in Health and Disease.
Oxford: Clarendon Press, 1992:399–436.
9. Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of
androgen and estrogen mRNA-containing cells in the rat brain: an in
situ hybridization study. J Comp Neurol 1990;294:76–95.
0. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable
testosterone for the treatment of male hypogonadism. Expert Opin
Pharmacother 2005;6:1751–9.
ey Words: baroreflex sensitivity y congestive heart failure y exercise
apacity y glucose metabolism y testosterone.
